Comparative Pharmacology
Head-to-head clinical analysis: ARISTOGEL versus NEOMYCIN SULFATE TRIAMCINOLONE ACETONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOGEL versus NEOMYCIN SULFATE TRIAMCINOLONE ACETONIDE.
ARISTOGEL vs NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; binds to androgen receptors, activating gene transcription and increasing protein synthesis.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Triamcinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, thereby decreasing prostaglandin and leukotriene synthesis, and exerts anti-inflammatory, antipruritic, and vasoconstrictive effects.
Aristogel is a topical gel containing 1% testosterone. The recommended adult dose is 5 g (50 mg testosterone) applied once daily to clean, dry, intact skin of shoulders, upper arms, and/or abdomen. Apply at approximately the same time each day, preferably in the morning.
Topical: Apply thin film to affected area 2-4 times daily. Otic: Instill 3-4 drops into ear canal 2-3 times daily. Not for systemic use.
None Documented
None Documented
Terminal elimination half-life is 12 hours. Given dosing frequency, steady-state achieved within 2 days; accumulation minimal with standard dosing.
Neomycin: 2-3 hours (normal renal function); in renal impairment, prolonged up to 12-24 hours. Triamcinolone acetonide: 2-5 hours (terminal).
Primarily renal (80%) as unchanged drug; 20% fecal via biliary elimination.
Neomycin: >90% orally administered excreted unchanged in feces; absorbed fraction (3-6%) excreted renally with 50% within 24 hours. Triamcinolone acetonide: primarily hepatic metabolism, renal excretion of metabolites (~40% as 11-keto derivatives), fecal excretion ~20%.
Category C
Category D/X
Corticosteroid
Corticosteroid